BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 11057850)

  • 21. Low-molecular-weight heparin (enoxaparin) as adjuvant therapy in the treatment of active ulcerative colitis: a randomized, controlled, comparative study.
    Zezos P; Papaioannou G; Nikolaidis N; Patsiaoura K; Papageorgiou A; Vassiliadis T; Giouleme O; Evgenidis N
    Aliment Pharmacol Ther; 2006 May; 23(10):1443-53. PubMed ID: 16669959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT).
    Turpie AG; Bauer KA; Davidson BL; Fisher WD; Gent M; Huo MH; Sinha U; Gretler DD;
    Thromb Haemost; 2009 Jan; 101(1):68-76. PubMed ID: 19132191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
    Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
    Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial.
    Lopes RD; Alexander KP; Marcucci G; White HD; Spinler S; Col J; Aylward PE; Califf RM; Mahaffey KW
    Eur Heart J; 2008 Aug; 29(15):1827-33. PubMed ID: 18519426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
    Levine M; Gent M; Hirsh J; Leclerc J; Anderson D; Weitz J; Ginsberg J; Turpie AG; Demers C; Kovacs M
    N Engl J Med; 1996 Mar; 334(11):677-81. PubMed ID: 8594425
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
    Agnelli G; Gallus A; Goldhaber SZ; Haas S; Huisman MV; Hull RD; Kakkar AK; Misselwitz F; Schellong S;
    Circulation; 2007 Jul; 116(2):180-7. PubMed ID: 17576867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis.
    Gonzalez-Fajardo JA; Arreba E; Castrodeza J; Perez JL; Fernandez L; Agundez I; Mateo AM; Carrera S; Gutiérrez V; Vaquero C
    J Vasc Surg; 1999 Aug; 30(2):283-92. PubMed ID: 10436448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis.
    Hull RD; Raskob GE; Pineo GF; Green D; Trowbridge AA; Elliott CG; Lerner RG; Hall J; Sparling T; Brettell HR
    N Engl J Med; 1992 Apr; 326(15):975-82. PubMed ID: 1545850
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of different dose regimens of enoxaparin in deep vein thrombosis therapy in pregnancy.
    Narin C; Reyhanoglu H; Tülek B; Onoglu R; Ege E; Sarigül A; Yeniterzi M; Durmaz I
    Adv Ther; 2008 Jun; 25(6):585-94. PubMed ID: 18568442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease.
    Kleber FX; Witt C; Vogel G; Koppenhagen K; Schomaker U; Flosbach CW;
    Am Heart J; 2003 Apr; 145(4):614-21. PubMed ID: 12679756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant.
    Michaels LA; Gurian M; Hegyi T; Drachtman RA
    Pediatrics; 2004 Sep; 114(3):703-7. PubMed ID: 15342842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Perioperative Bridging with Enoxaparin. Results of the Prospective BRAVE Registry with 779 Patients].
    Omran H; Hammerstingl C; Paar WD;
    Med Klin (Munich); 2007 Oct; 102(10):809-15. PubMed ID: 17928964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
    Holzheimer RG
    Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduction of ischemic sequelae following spontaneous subarachnoid hemorrhage: a double-blind, randomized comparison of enoxaparin versus placebo.
    Wurm G; Tomancok B; Nussbaumer K; Adelwöhrer C; Holl K
    Clin Neurol Neurosurg; 2004 Mar; 106(2):97-103. PubMed ID: 15003298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis.
    Levine MN; Hirsh J; Gent M; Turpie AG; Weitz J; Ginsberg J; Geerts W; LeClerc J; Neemeh J; Powers P
    Thromb Haemost; 1995 Aug; 74(2):606-11. PubMed ID: 8584992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of venous thromboembolism in the acute treatment phase after spinal cord injury: a randomized, multicenter trial comparing low-dose heparin plus intermittent pneumatic compression with enoxaparin.
    Spinal Cord Injury Thromboprophylaxis Investigators
    J Trauma; 2003 Jun; 54(6):1116-24; discussion 1125-6. PubMed ID: 12813332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Hemorrhagic complications and thrombotic phenomena in oral anticoagulation of elderly patients].
    Selva O'Callaghan A; San José Laporte A; Fuentes Camps I; Nicolau Fuste J; Piqueras Carrasco J; Vilardell Tarres M
    Rev Clin Esp; 1997 May; 197(5):323-8. PubMed ID: 9280965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol].
    Márk L; Márki-Zay J; Fodor L; Kondacs A; Paragh G; Katona A
    Orv Hetil; 2005 Apr; 146(16):739-43. PubMed ID: 15889670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bridging of oral anticoagulation with low-molecular-weight heparin: experience in 373 patients with renal insufficiency undergoing invasive procedures.
    Hammerstingl C; Omran H;
    Thromb Haemost; 2009 Jun; 101(6):1085-90. PubMed ID: 19492151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.